Clascoterone can improve moderate-to-severe facial acne, but trials show a modest benefit rather than a dramatic clearing effect. It is a topical androgen-receptor inhibitor that may complement established treatments, not a proven replacement for them. The strongest evidence covers 12 weeks of treatment in adolescents and adults. Longer-term findings help describe tolerability, but leave important questions about comparative effectiveness and broader populations.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How effective was clascoterone in clinical trials?
- Who does the evidence represent?
- What do we know about longer use and safety?
- Where does clascoterone fit in acne care?
- Approval and practical use differ by region
How effective was clascoterone in clinical trials?
Two randomized, double-blind trials compared clascoterone 1% cream with its inactive vehicle in 1,440 people. After 12 weeks, 18.8% and 20.9% of clascoterone users achieved "clear" or "almost clear" skin with sufficient improvement. The corresponding vehicle results were 8.7% and 6.6%, according to the NIH DailyMed prescribing information. Those percentages show a real treatment effect, but most participants did not reach the trial's success threshold.
Clascoterone also reduced both major lesion types more than vehicle. Its absolute advantage was 7.3–8.7 fewer non-inflammatory lesions and 3.9–7.5 fewer inflammatory lesions. Non-inflammatory lesions include clogged pores, while inflammatory lesions are red or swollen spots. A person may therefore see worthwhile improvement without becoming clear or almost clear by week 12.
Who does the evidence represent?
The pivotal results apply most directly to people aged 12 or older with moderate-to-severe facial acne. Of the analyzed participants, 45% were ages 12–17 and 62% were female, so the studies included substantial adolescent and female representation. However, 91% of participants were White.
That imbalance limits confidence about whether the size of the benefit and the pattern of adverse effects are identical across more diverse populations. The trials also focused on facial acne. They do not establish the same level of evidence for acne concentrated on the chest, back, or other areas.
What do we know about longer use and safety?
A nine-month open-label extension followed participants beyond the controlled trials. Of 600 enrolled participants, 343 completed treatment. Because everyone knew which treatment they received and there was no concurrent control group, the study supports longer-term tolerability more strongly than comparative effectiveness. Among 598 treated participants, 18.1% experienced treatment-emergent adverse events.
In participants previously assigned clascoterone, facial redness occurred in 8.0% and scaling or dryness in 10.0%, as reported in the Journal of Drugs in Dermatology extension study. The U.S. label also warns about local irritation and suppression of the hypothalamic-pituitary-adrenal, or HPA, axis. This hormone-control system helps regulate the body's response to stress. After two weeks of high-use testing, suppression occurred in one of 20 adults and two of 22 adolescents; testing normalized four weeks after treatment stopped.
Where does clascoterone fit in acne care?
The American Academy of Dermatology gives topical clascoterone a conditional recommendation. By comparison, it strongly recommends benzoyl peroxide, topical retinoids, and selected treatment combinations in its updated acne-management guidelines.
That distinction does not mean clascoterone lacks value. It means treatment choice should depend more heavily on the individual situation, including acne pattern, previous response, irritation, and the rest of the regimen. Useful points to discuss with a clinician include:.
- Whether the acne matches the facial, moderate-to-severe population studied.
- Whether clascoterone would be added to an existing regimen or used instead of another topical treatment.
- How to handle redness, dryness, scaling, or worsening irritation.
- When to judge the response, given that the controlled evidence measured results at 12 weeks.
Approval and practical use differ by region
U.S. labeling authorizes clascoterone 1% cream, sold as Winlevi, for people aged 12 and older. It directs users to apply a thin layer twice daily. The European Medicines Agency reports that Winlevi was authorized across the European Union on October 17, 2025.
The authorization covers adults and facial acne in adolescents from age 12, with restrictions addressing theoretical adolescent HPA-axis and pregnancy risks. The EMA characterized the benefit as modest but clinically relevant in its Winlevi regulatory overview. Readers should follow the instructions for their own region and prescription rather than transferring eligibility or precautions from another jurisdiction. Before starting, confirm the intended treatment area, twice-daily schedule, and what irritation or hormone-related concerns should prompt medical advice.
